Key Takeaway: Jazz Pharmaceuticals has announced that it will report its third quarter financial results for 2025 on November 5, 2025. The report will be followed by a live audio webcast hosted by company management to discuss the results and provide a business update. Interested parties are encouraged to register in advance for the webcast.
Price reaction · baseline $138.52 (2025-10-22 close) · hit after-hours · 1 other JAZZ headline(s) in the window, move may be shared
day 0 close · peak
-0.2%
Market Sentiment Analysis
POSITIVE FACTORS
Jazz Pharmaceuticals is set to report its financial results, indicating ongoing business activity.
The company is dedicated to developing life-changing medicines, highlighting its commitment to innovation.
The live webcast will provide insights into the company's financial performance and future outlook.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
2.1%
average across 9 past catalysts
Lead asset
GWP42004
Phase 2 · Diabetes Mellitus, Type 2
Full Press Release Details
DUBLIN,Oct. 22, 2025/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EST / 9:30 p.m. GMT to discuss 2025 third quarter financial results and provide a business and financial update.
Interested parties may register for the call in advancehereor via the Investors section of the Jazz Pharmaceuticals website atwww.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq:JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visitwww.jazzpharmaceuticals.comfor more information.